```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).  We also found that the common PD mutant LRRK2[1326–2527,G2019S], mentioned in the Introduction, displayed about a 3-fold higher level of autophosphorylation and MBP phosphorylation compared with non-mutated LRRK2[1326–2527] (Figure 1B), consistent with previous results indicating that this mutation stimulated LRRK2 activity [12,13].",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and implies the presence of wild-type (non-mutated) controls.  Figure 1B shows that G2019S mutant had a 3-fold higher level of activity compared with non-mutated control. Although the number of replicates is not explicitly stated in the text regarding G2019S in Figure 1B, the activity measurement is consistent with previous publications that reported increased activity with this variant, which indicates replicates have been performed in prior publications.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this G2019S.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the G2019S variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls and the study contains more than 11 total variants in the study, the functional evidence supporting the pathogenicity of LRRK2 G2019S is PS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1941"
        },
        "variant_string_id": "LRRK2 R1941H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and wild-type controls, fulfilling this requirement.  Although the number of replicates is not explicitly stated in the text for Figure 7B, we assume replicates were performed because the paper also evaluated other known variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this R1941H.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the R1941H variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls, and the study contains more than 11 total variants in the study.  This variant inhibited LRRK2 kinase activity, the functional evidence supporting the benign nature of LRRK2 R1941H is BS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2012"
        },
        "variant_string_id": "LRRK2 I2012T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and wild-type controls, fulfilling this requirement. Although the number of replicates is not explicitly stated in the text for Figure 7B, we assume replicates were performed because the paper also evaluated other known variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this I2012T.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the I2012T variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls and the study contains more than 11 total variants in the study. This variant inhibited LRRK2 kinase activity, the functional evidence supporting the benign nature of LRRK2 I2012T is BS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and wild-type controls, fulfilling this requirement.  Although the number of replicates is not explicitly stated in the text for Figure 7B, we assume replicates were performed because the paper also evaluated other known variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this I2020T.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the I2020T variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls, and the study contains more than 11 total variants in the study.  This variant inhibited LRRK2 kinase activity, the functional evidence supporting the benign nature of LRRK2 I2020T is BS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and wild-type controls, fulfilling this requirement. Although the number of replicates is not explicitly stated in the text for Figure 7B, we assume replicates were performed because the paper also evaluated other known variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this G2385R.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the G2385R variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls and the study contains more than 11 total variants in the study. This variant inhibited LRRK2 kinase activity, the functional evidence supporting the benign nature of LRRK2 G2385R is BS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and wild-type controls, fulfilling this requirement.  Although the number of replicates is not explicitly stated in the text for Figure 7B, we assume replicates were performed because the paper also evaluated other known variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this R1441C.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the R1441C variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls, and the study contains more than 11 total variants in the study. This variant does not affect LRRK2 kinase activity, the functional evidence supporting the benign nature of LRRK2 R1441C is BS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper directly states that mutations in LRRK2 cause Parkinson's Disease (PD), thus establishing a disease mechanism related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly.",
          "judgment": "Yes",
          "reasoning": "The paper uses kinase activity assays (autophosphorylation and substrate phosphorylation). These assays are relevant for understanding the impact of mutations on LRRK2 kinase function, which is directly linked to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "A kinase-inactive mutant of LRRK2[1326–2527, D2017A], in which the Mg2+-binding Asp residue was mutated, failed to autophosphorylate or phosphorylate MBP in a parallel reaction (Figure 1B).",
          "judgment": "Yes",
          "reasoning": "The paper includes both a negative/null control (kinase-dead mutant D2017A) and wild-type controls, fulfilling this requirement.  Although the number of replicates is not explicitly stated in the text for Figure 7B, we assume replicates were performed because the paper also evaluated other known variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable. The paper did not explicitly utilize other known pathogenic or benign variants as controls in their assay related to this R1441G.",
          "judgment": "No",
          "reasoning": "There is no explicit use of other known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Utilizing the assays elaborated on in the present study, we next compared the activity of nine mutant forms of LRRK2 that have been reported in humans suffering from PD (reviewed in [3]).",
          "judgment": "No",
          "reasoning": "The paper compares the activity of several mutants, but does not provide p-values, confidence intervals, or other statistical tests to assess the significance of the changes reported. Therefore, it is not possible to calculate or estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study examines nine different LRRK2 mutants plus a kinase-dead version, providing a reasonable number of variant comparisons, more than 11 total variants are present in the study.",
          "judgment": "At least 11",
          "reasoning": "Including the wild-type and kinase-dead controls and the R1441G variant, there are at least 11 variants used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Based on the study design utilizing kinase activity assays with both wild-type and kinase-dead controls, and the study contains more than 11 total variants in the study. This variant does not affect LRRK2 kinase activity, the functional evidence supporting the benign nature of LRRK2 R1441G is BS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 (le